— Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected.
— Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected
— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million
— Third-quarter gross margin was 82%, down from 83% reported a year earlier
— Announced initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading Pivotal Randomized Controlled Trial during the quarter
— Expects full-year 2020 revenue to be in the range of $846 million to $877 million, up 10% to 14% respectively
— Confirms full-year 2020 unadjusted operating margin guidance in the range of 28% to 30%